Lab study explores how JAK inhibitors affect immune cells in arthritis
NCT ID NCT03755297
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how JAK-STAT inhibitors, a type of drug used for rheumatoid arthritis, affect certain immune cells called regulatory B cells. Researchers analyzed blood samples from 27 patients to see if these drugs could boost anti-inflammatory functions. The study was terminated early, so findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JAK-STAT inhibitors (tested in blood samples in the lab)
What this could lead to
If successful, this could point toward a better understanding of how JAK inhibitors work in rheumatoid arthritis, potentially leading to improved treatments.
What could go wrong
This was a small, early-stage lab study that was terminated, so results are limited. It does not test a new drug directly in patients, so any benefits are uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital of Montpellier
Montpellier, 34, France